跳至主要内容
临床试验/CTRI/2019/09/021158
CTRI/2019/09/021158进行中(未招募)4 期

A Real-World, Prospective, Observational Study to Evaluatethe Safety and Effectiveness of Rivaroxaban (Xarelto®) forPrevention of Stroke and Systemic Embolism in IndianPatients with Non-valvular Atrial Fibrillation (NVAF) - XARI

Bayer Zydus Pharma Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • Patient should be an adult female or male, >=18 years of age;
  • Patient should be diagnosed with NVAF and initiated with rivaroxaban treatment for
  • prevention of stroke or systemic embolism per investigatorâ??s routine treatment practice;
  • Patient should not have received rivaroxaban in the past;
  • Patient/patientâ??s legally acceptable representative should be willing to provide written
  • informed consent.

排除标准

  • 1. Patient has contraindications to receive rivaroxaban therapy according to local prescribing
  • information;
  • 2. Patient is receiving anticoagulant therapy for indication other than NVAF and that needs to
  • be continued as per discretion of treating physician;
  • 3. Patient is participating in an investigational program with interventions outside of routine
  • clinical practice.

研究者

相似试验